Pharmamarketeer

Satsuma Pharma begins phase 3 EMERGE trial of STS101 to treat migraine

Satsuma Pharmaceuticals, Inc, a clinical─stage biopharmaceutical company, announced dosing of the first patient in its phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the

Medhc-fases-banner
Advertentie(s)